Financhill
Sell
35

TTNP Quote, Financials, Valuation and Earnings

Last price:
$3.84
Seasonality move :
104.08%
Day range:
$3.70 - $4.11
52-week range:
$3.03 - $14.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.39x
Volume:
2.5K
Avg. volume:
23K
1-year change:
-46.92%
Market cap:
$3.4M
Revenue:
$1K
EPS (TTM):
-$5.21

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Titan Pharmaceuticals has 3683.78% upside to fair value with a price target of -- per share.

TTNP vs. S&P 500

  • Over the past 5 trading days, Titan Pharmaceuticals has underperformed the S&P 500 by -5.16% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Titan Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Titan Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Titan Pharmaceuticals reported revenues of --.

Earnings Growth

  • Titan Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Titan Pharmaceuticals reported earnings per share of -$0.85.
Enterprise value:
552.5K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $61K -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$10.2M -$7.3M -$4.6M -$1.9M -$666K
EBITDA -$10M -$7.2M -$4.6M -$1.9M -$666K
Diluted EPS -$15.39 -$7.41 -$5.21 -$2.62 -$0.85
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $7.3M $7.2M $3.6M $8M $2.9M
Total Assets $8.1M $8M $4.1M $8.1M $2.9M
Current Liabilities $4.2M $2.7M $2.6M $1.4M $483K
Total Liabilities $4.6M $2.9M $2.7M $1.4M $483K
Total Equity $3.5M $5.1M $1.4M $6.6M $2.4M
Total Debt $659K -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$8.2M -$7.1M -$3.9M -$2.2M -$506K
Cash From Investing -- -- -- $504K --
Cash From Financing $5M -- -- $406K -$62K
Free Cash Flow -$8.2M -$7.1M -$3.9M -$2.2M -$506K
TTNP
Sector
Market Cap
$3.4M
$35M
Price % of 52-Week High
25%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-46.92%
-38.53%
Beta (5-Year)
1.272
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $3.70
200-day SMA
Sell
Level $4.40
Bollinger Bands (100)
Buy
Level 3.37 - 3.87
Chaikin Money Flow
Sell
Level -1.2B
20-day SMA
Sell
Level $3.72
Relative Strength Index (RSI14)
Sell
Level 49.53
ADX Line
Buy
Level 7.73
Williams %R
Neutral
Level -67.2241
50-day SMA
Sell
Level $3.76
MACD (12, 26)
Sell
Level -0.01
25-day Aroon Oscillator
Buy
Level 4
On Balance Volume
Neutral
Level 1.3B

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-67.1557)
Sell
CA Score (Annual)
Level (-5.1377)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.0699)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Stock Forecast FAQ

In the current month, TTNP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TTNP average analyst price target in the past 3 months is --.

  • Where Will Titan Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Titan Pharmaceuticals share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Titan Pharmaceuticals?

    Analysts are divided on their view about Titan Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Titan Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.

  • What Is Titan Pharmaceuticals's Price Target?

    The price target for Titan Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is TTNP A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Titan Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of TTNP?

    You can purchase shares of Titan Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Titan Pharmaceuticals shares.

  • What Is The Titan Pharmaceuticals Share Price Today?

    Titan Pharmaceuticals was last trading at $3.84 per share. This represents the most recent stock quote for Titan Pharmaceuticals. Yesterday, Titan Pharmaceuticals closed at $3.70 per share.

  • How To Buy Titan Pharmaceuticals Stock Online?

    In order to purchase Titan Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is it Too Late to Buy Gold?
Is it Too Late to Buy Gold?

Amid deep uncertainties about the future of the US economy,…

Is NextEra Energy a Stock to Hold Forever?
Is NextEra Energy a Stock to Hold Forever?

NextEra Energy (NYSE:NEE) share price sold off hard in recent…

Why Did Bill Ackman Buy Alphabet Stock?
Why Did Bill Ackman Buy Alphabet Stock?

Bill Ackman has become famous in the investing world for…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Sell
27
SAIA alert for Apr 28

Saia [SAIA] is down 3.49% over the past day.

Sell
48
APPF alert for Apr 28

AppFolio [APPF] is up 5.02% over the past day.

Sell
15
KNSL alert for Apr 28

Kinsale Capital Group [KNSL] is up 0.99% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock